Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations.
作者信息
Yu P H, Lai C T, Boulton A A
出版信息
BMJ. 1996 Mar 16;312(7032):703-4; author reply 704-5. doi: 10.1136/bmj.312.7032.703b.
Abstract
摘要
相似文献
1
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations.
BMJ. 1996 Mar 16;312(7032):703-4; author reply 704-5. doi: 10.1136/bmj.312.7032.703b.
2
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline is effective and safe in early stages.
BMJ. 1996 Mar 16;312(7032):703; author reply 704-5.
3
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients.
BMJ. 1996 Mar 16;312(7032):702; author reply 704-5. doi: 10.1136/bmj.312.7032.702.
4
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used.
BMJ. 1996 Mar 16;312(7032):704; author reply 704-5.
5
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation.
BMJ. 1996 Mar 16;312(7032):704-5. doi: 10.1136/bmj.312.7032.704.
6
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality.
BMJ. 1996 Mar 16;312(7032):702; author reply 704-5.
7
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
BMJ. 1996 Mar 16;312(7032):702-3; author reply 704-5.
8
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death.
BMJ. 1996 Mar 16;312(7032):703; author reply 704-5. doi: 10.1136/bmj.312.7032.703.
9
[Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
Rev Neurol (Paris). 1996 Feb;152(2):103-5.
10
Strategies in the treatment of early Parkinson's disease.
Acta Neurol Scand Suppl. 1993;146:50-3.
引用本文的文献
1
MPP(+)-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress.
Naunyn Schmiedebergs Arch Pharmacol. 2011 Aug;384(2):157-67. doi: 10.1007/s00210-011-0660-8. Epub 2011 Jun 12.
2
Monoamine oxidase inhibitors. A perspective on their use in the elderly.
Drugs Aging. 1998 Nov;13(5):341-55. doi: 10.2165/00002512-199813050-00002.
3
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1997 Aug;63(2):228-34. doi: 10.1136/jnnp.63.2.228.
4
Mortality associated with selegiline in Parkinson's disease. What do the available data mean?
Drug Saf. 1997 May;16(5):289-94. doi: 10.2165/00002018-199716050-00001.
本文引用的文献
1
The colorful past and bright future of monoamine oxidase research.
Prog Brain Res. 1995;106:1-22. doi: 10.1016/s0079-6123(08)61197-8.
2
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
BMJ. 1995 Dec 16;311(7020):1602-7. doi: 10.1136/bmj.311.7020.1602.
3
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
J Med Chem. 1992 Oct 2;35(20):3705-13. doi: 10.1021/jm00098a017.
Zotero 插件